Literature DB >> 1308927

Cyclosporin A: antiparasite drug, modulator of the host-parasite relationship and immunosuppressant.

L H Chappell1, J M Wastling.   

Abstract

Cyclosporin A (CsA), a cyclic undecapeptide with powerful properties of immunosuppression, acts on parasitic infections in laboratory animals in various ways. The outcome of drug administration in vivo varies with timing of treatment relative to infection, route of administration, dose and number of treatments applied. CsA is clearly antiparasitic against malaria, schistosomes, adult tapeworms, metacestodes and filarial nematodes. By contrast, it acts as an immunomodulator against trypanosomes and Giardia, by exacerbating infection; in the case of Leishmania spp. the drug acts variously. In some other infections CsA acts both as an antiparasite drug and as an immunosuppressant (Toxoplasma, avian coccidiosis and gastrointestinal nematodes). This range of activities is reviewed and possible modes of action discussed in the light of emerging data on in vitro drug activity and on putative receptor binding. The potential value of a non-immunosuppressive analogue of CsA in the control of parasitic infections of humans and domestic animals is considered but this paper lays particular stress on the seminal role of CsA as a laboratory tool.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1308927     DOI: 10.1017/s0031182000075338

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  12 in total

1.  Cloning and biochemical characterization of the cyclophilin homologues from the free-living nematode Caenorhabditis elegans.

Authors:  A P Page; K MacNiven; M O Hengartner
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries.

Authors:  M Lizotte-Waniewski; W Tawe; D B Guiliano; W Lu; J Liu; S A Williams; S Lustigman
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers.

Authors:  D A van Schalkwyk; J C Walden; P J Smith
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

Authors:  Wai-Lok Yau; Thierry Blisnick; Jean-François Taly; Manuela Helmer-Citterich; Cordelia Schiene-Fischer; Olivier Leclercq; Jing Li; Dirk Schmidt-Arras; Miguel A Morales; Cedric Notredame; Daniel Romo; Philippe Bastin; Gerald F Späth
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

5.  Crystal structure of the cyclophilin-like domain from the parasitic nematode Brugia malayi.

Authors:  V Mikol; D Ma; C K Carlow
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

Review 6.  Cyclophilin nomenclature problems, or, 'a visit from the sequence police'.

Authors:  Daniel W Nebert; Nickolas A Sophos; Vasilis Vasiliou; David R Nelson
Journal:  Hum Genomics       Date:  2004-08       Impact factor: 4.639

7.  Prevalence of cryptosporidium infection in immunocompromised patients, in South-west of iran, 2009-10.

Authors:  A Balouty Dehkordy; A Rafiei; Sm Alavi; Sm Latifi
Journal:  Iran J Parasitol       Date:  2010-12       Impact factor: 1.012

8.  Enzymes: An integrated view of structure, dynamics and function.

Authors:  Pratul K Agarwal
Journal:  Microb Cell Fact       Date:  2006-01-12       Impact factor: 5.328

9.  In silico analysis of the cyclophilin repertoire of apicomplexan parasites.

Authors:  Jürgen Krücken; Gisela Greif; Georg von Samson-Himmelstjerna
Journal:  Parasit Vectors       Date:  2009-06-25       Impact factor: 3.876

10.  Functional analysis of Leishmania major cyclophilin.

Authors:  Vyacheslav Yurchenko; Zhu Xue; Barbara Sherry; Michael Bukrinsky
Journal:  Int J Parasitol       Date:  2007-10-10       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.